April 27 Ignyta Inc:
* Ignyta updates progress towards entrectinib dual trk and ros1 NDA submissions
* Ignyta - tracking towards dual NDA submissions in TRK and ros1 in 2018 if supported by clinical data, anticipated us commercial launch in both indications in 2019 Source text for Eikon: Further company coverage:
REFILE-India's Infosys says reassessing long-term goals due to tougher market
Bengaluru, June 24 Infosys Ltd, India's second-biggest software services exporter, is re-evaluating its long-term targets because tougher market conditions have made them appear "daunting", the company's chairman said on Saturday.
WORLD NEWS SCHEDULE AT 1400 GMT/10 AM ET
Iraqi forces free hundreds of civilians in Mosul Old City battles as death toll mounts